Technology ID
TAB-2663
HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct
E-Numbers
E-231-2013-0
Lead Inventor
Lal, Renu (CDC)
Co-Inventors
Owen, Sherry (CDC)
Applications
Vaccines
Therapeutics
Therapeutic Areas
Infectious Disease
Development Status
- Early-stage
- In vitro data available
Lead IC
CDC
ICs
CDC
CDC scientists developed immunogenic multi-clade, multivalent (HIV1MCMV) recombinant constructs for use as HIV-1 vaccines. These polypeptides include immunogenic CTL, T- and/or B-cell determinants that are capable of eliciting broad and effective immune responses against diverse subtypes of HIV-1. It is believed that these HIV-1 constructs provide universal vaccines, capable of effective use in any part of the world affected by the HIV-1 epidemic. The construct contains specific cellular targeting epitopes that allow optimized antigen processing and recognition, and the design of the construct allows for the addition or deletion of epitopes. Additionally, the construct may be used to develop multi-pathogen vaccines by combination with other epitope-based constructs.
Commercial Applications
- Development of HIV-1 vaccine
Competitive Advantages
- Allows easy epitope-tailoring
- Broad spectrum protection against HIV-1
- Unlike other HIV-vaccination strategies, this approach specifically primes both arms of the immune system for improved protection
- Can be combined with other epitope-based constructs to generate multi-pathogen vaccines
Licensing Contact: